Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera
SEOUL, South Korea--(BUSINESS WIRE)--A clinical-staged proprietary platform technology biotech company Genexine (KQ 095700, CEO Neil…